Levodopa Tables:

Pharmacokinetics

Bioavailability Peak plasma level Plasma half-life Active metabolites Elimination
variable 30%* 1 to 2 hours 60 to 90 minutes dopamine predominantly extrarenal
*Only about 1% reaches the cerebrospinal fluid space. However, the addition of a decarboxylase inhibitor increases the availability in the plasma and in the central nervous system considerably. Dopamine is metabolized by the monoamine-oxidase (MAO) and the catechol-O-methyltransferase (COMT).

Dose
Indication Administration
Initial loading dose
Dose Interval
Maintenance dose
Dose Interval
Parkinson's disease oral 50 mg + 12.5 mg DI* 8 to 12 hours 100-200 mg + 25-50 mg DI* 4 to 8 hours**
*DI = decarboxylase inhibitor benserazide (in madopar) or carbidopa (in sinemet).
**The initial dose should, in a first step, be raised to a daily maintenance dose of 300 to 400 mg (in 3 to 5 single doses). Only after a waiting period of several weeks should the dose be increased further. Occasionally higher daily doses are given. There may be inferior fluctuation with sustained release preparations.

Copyright © 1996 Infomed-Verlags AG